These allosteric effects can be modulated through the action of carnitine acetyltransferase (CAT), a mitochondrial isoenzyme that transfers the acetyl groups from acetyl-CoA to carnitine, forming acetylcarnitine
incorrect dosing may exacerbate these effects Gallbladder problems GLP-1 receptor agonist use has been associated with gallbladder disease, including gallstones and cholecystitis Hypoglycaemia If retatrutide is used alongside insulin or sulfonylureas, there is an increased risk of low blood glucose Call 999 or go to A&E immediately if you experience: Difficulty breathing, throat swelling, or any signs of anaphylaxis Severe abdominal pain (which may indicate pancreatitis or a gallbladder problem) Rapid heart rate, dizziness, or collapse following injection Contact your GP or NHS 111 if you experience: Persistent nausea, vomiting, or inability to tolerate food or fluids Signs of infection at the injection site (increasing redness, warmth, swelling, or discharge) Upper right abdominal pain or pain radiating to the shoulder (possible gallbladder symptoms) Any unexpected or concerning symptoms following use If you feel unwell after using an unlicensed injectable, stop use immediately and bring the vial and any packaging with you when seeking medical attention, as this will assist healthcare professionals in assessing your situation
Hatch, A
Should patients with existing AF avoid GLP-1 medications
What Does the Clinical Research Show
